Robert Edfors

Robert Edfors

Auto-generated profile, based on publicly available information

Robert Edfors

Karolinska Institutet, Nobels väg 6, SE-171 77 Stockholm

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2014 in JAMA
Verified
Journal Article
Open access
PDF file
JCJuan Jesús Carrero
Juan Jesús Carrero
MEMarie Evans
Marie Evans
KSKarolina Szummer
Karolina Szummer
JSJonas Spaak
Jonas Spaak
LLLars Lindhagen
Lars Lindhagen
TJTomas Jernberg
Tomas Jernberg
Patients with chronic kidney disease (CKD) experience a marked increased risk of atherothrombotic and thromboembolic complications, such as myocardial infarction and stroke, and simultaneously have an increased risk of bleeding.1,2 Both of these risks increase exponentially as renal function deteriorates. Embolism from the heart is a major cause of ischemic stroke, particularly in atrial fibrillation. Patients with concomitant atrial fibrillation and reduced kidney function are increasingly common, not only because both conditions share common risk factors, but also because they promote one another.3,4 Not unexpectedly, patients with CKD and atrial fibrillation have higher risk of ischemic stroke and thrombembolism than patients without CKD.5,6

1 April 2016 in JACC
Verified
Journal Article
Closed access
MEMarie Evans
Marie Evans
JCJuan-Jesus Carrero
Juan-Jesus Carrero
KSKarolina Szummer
Karolina Szummer
AÅAxel Åkerblom
Axel Åkerblom
RERobert Edfors
Robert Edfors
TJTomas Jernberg
Tomas Jernberg

17 February 2015 in JAMA
Verified
Journal Article
Closed access
PDF file
KSKarolina Szummer
Karolina Szummer
JOJonas Oldgren
Jonas Oldgren
LLLars Lindhagen
Lars Lindhagen
JCJuan Jesus Carrero
Juan Jesus Carrero
MEMarie Evans
Marie Evans
TJTomas Jernberg
Tomas Jernberg
Research from JAMA — Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non–ST-Segment Elevation Myocardial Infarction

24 March 2018 in Heart
Verified
Journal Article
Closed access
PDF file
RERobert Edfors
Robert Edfors
ASAnders Sahlén
Anders Sahlén
KSKarolina Szummer
Karolina Szummer
HRHenrik Renlund
Henrik Renlund
MEMarie Evans
Marie Evans
TJTomas Jernberg
Tomas Jernberg
Objectives: We aimed to analyse outcomes of ticagrelor and clopidogrel stratified by estimated glomerular filtration rate (eGFR) in a large unselected cohort of patients with acute myocardial infarction (MI). Methods: We used follow-up data in MI survivors discharged on ticagrelor or clopidogrel enrolled in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry. The association between ticagrelor versus clopidogrel and the primary composite outcome of death, MI or stroke and the secondary outcome rehospitalisation with bleeding diagnosis at 1 year, was studied using adjusted Cox proportional hazards models, stratifying after eGFR levels. Results: In total, 45 206 patients with MI discharged on clopidogrel (n=33 472) or ticagrelor (n=11 734) were included. The unadjusted 1-year event rate for the composite endpoint of death, MI or stroke was 7.0%, 18.0% and 48.0% for ticagrelor treatment and 11.0%, 33.0% and 64.0% for clopidogrel treatment in patients with eGFR>60 (n=33 668), eGFR30–60 (n=9803) and eGFR<30 (n=1735), respectively. After adjustment, ticagrelor as compared with clopidogrel was associated with a lower 1-year risk of the composite outcome (eGFR>60: HR 0.87, 95% CI 0.76 to 99, eGFR30–60: 0.82 (0.70 to 0.97), eGFR<30: 0.95 (0.69 to 1.29), P for interaction=0.55) and a higher risk of bleeding (eGFR>60: HR 1.10, 95% CI 0.90 to 1.35, eGFR30–60: 1.13 (0.84 to 1.51), eGFR<30: 1.79 (1.00 to 3.21), P for interaction=0.30) across the eGFR strata. Conclusions: Treatment with ticagrelor as compared with clopidogrel in patients with MI was associated with lower risk for the composite of death, MI or stroke and a higher bleeding risk across all strata of eGFR. Of caution, bleeding events were more abundant in patients with eGFR<30.

2 July 2022 in European Heart Journal Open
Verified
Journal Article
Open access
PDF file
THTora Hellgren
Tora Hellgren
MBMai Blöndal
Mai Blöndal
JJJarle Jortveit
Jarle Jortveit
TFTamas Ferenci
Tamas Ferenci
JFJonas Faxén
Jonas Faxén
RERobert Edfors
Robert Edfors
Data on how differences in risk factors, treatments, and outcomes differ between sexes in European countries are scarce. We aimed to study sex-related differences regarding baseline characteristics, in-hospital managements, and mortality of ST-elevation myocardial infarction (STEMI) patients in different European countries. Patients over the age of 18 with STEMI who were treated in hospitals in 2014–17 and registered in one of the national myocardial infarction registers in Estonia (n = 5817), Hungary (n = 30 787), Norway (n = 33 054), and Sweden (n = 49 533) were included. Cardiovascular risk factors, hospital treatment, and recommendation of discharge medications were obtained from the infarction registries. The primary outcome was mortality, in-hospital, after 30 days and after 1 year. Logistic and cox regression models were used to study the associations of sex and outcomes in the respective countries. Women were older than men (70–78 and 62–68 years, respectively) and received coronary angiography, percutaneous coronary intervention, left ventricular ejection fraction assessment, and evidence-based drugs to a lesser extent than men, in all countries. The crude mortality in-hospital rates (10.9–15.9 and 6.5–8.9%, respectively) at 30 days (13.0–19.9 and 8.2–10.9%, respectively) and at 1 year (20.3–28.1 and 12.4–17.2%, respectively) after hospitalization were higher in women than in men. In all countries, the sex-specific differences in mortality were attenuated in the adjusted analysis for 1-year mortality. Despite improved awareness of the sex-specific inequalities on managing patients with acute myocardial infarction in Europe, country-level data from this study show that women still receive less guideline-recommended management.

12 March 2021 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
MBMai Blöndal
Mai Blöndal
TATiia Ainla
Tiia Ainla
JEJaan Eha
Jaan Eha
PLPiret Lõiveke
Piret Lõiveke
TMToomas Marandi
Toomas Marandi
AJAndrás Jánosi
András Jánosi
Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden. Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014–2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013–2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden. This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics’ definitions that need to be further explored.